RYTM
RHYTHM PHARMACEUTICALS, INC.
RHYTHM PHARMACEUTICALS, INC. (RYTM) has 9 SEC Form 4 filings (14 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Jul 2, 2026.
Insiders have net sold $4.1M over the trailing 6 months.
- Industry:Biotechnology
- CEO:David Meeker
- Employees:283
- HQ:Boston, MA, US
- IPO:2017-10-09
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.1M
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$7.1B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 37,000 | $3.7M | Jun 24 | SEC ↗ | |
German Christopher PaulFirst filing | Corporate Controller & CAO | Sale | 4,643 | $428K | May 19 | SEC ↗ |
Related companies
RHYTHM PHARMACEUTICALS, INC. is in the Healthcare sector.